Charles River extends Huntington’s Disease collaboration, shutters site in San Diego

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Radachynskyi)
(Image: Getty/Radachynskyi)

Related tags: Charles river laboratories

Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.

Charles River Laboratories​ and the CHDI Foundation have been collaborating on drug discovery and development for Huntington’s disease (HD) since 2005.

Over the course of the 14-year relationship, the companies have identified novel potential drug targets, bred and validated translational research animal models, and generated proof-of-concept molecules.

The companies also have evaluated the potential efficacy of both small molecule and biologic candidates in preclinical models of HD, a genetic neurological disease that causes the progressive dysfunction of nerve cells in the brain.

Under the extended contract, Charles River will provide various services, including complex primary neuronal assay development, high-content and fragment-based screening, absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics (PK), among others.

Streamlining operations

Also earlier this month, Charles River announced plans to close its research model production facility in San Diego, CA, which currently employs 24 people. A company spokesperson told us in a statement:

“As part of our continuing efforts to streamline operations and enhance efficiencies, we have made the decision to close our research model production facility in San Diego and relocate all services and production to our Hollister site.

“Charles River is committed to maintaining its world-class client service and will ensure that the site closure will not impact availability or service.”

The permanent closure will be effective May 20, 2019, per the WARN notice.

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us


View more